ASND Valuation
Ascendis Pharma A/S
$
191.490
- Overview
- Forecast
- Valuation
- Earnings
ASND Relative Valuation
ASND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASND is overvalued; if below, it's undervalued.
Historical Valuation
Ascendis Pharma A/S (ASND) is now in the Fair zone, suggesting that its current forward PS ratio of 12.35 is considered Fairly compared with the five-year average of -20.28. The fair price of Ascendis Pharma A/S (ASND) is between 175.18 to 255.53 according to relative valuation methord.
Relative Value
Fair Zone
175.18-255.53
Current Price：191.49
Fair
-98.72
PE
1Y
3Y
5Y
Trailing
Forward
-116.31
EV/EBITDA
Ascendis Pharma A/S. (ASND) has a current EV/EBITDA of -116.31. The 5-year average EV/EBITDA is -23.34. The thresholds are as follows: Strongly Undervalued below -63.47, Undervalued between -63.47 and -43.40, Fairly Valued between -3.28 and -43.40, Overvalued between -3.28 and 16.78, and Strongly Overvalued above 16.78. The current Forward EV/EBITDA of -116.31 falls within the Strongly Undervalued range.
-156.79
EV/EBIT
Ascendis Pharma A/S. (ASND) has a current EV/EBIT of -156.79. The 5-year average EV/EBIT is -21.93. The thresholds are as follows: Strongly Undervalued below -67.50, Undervalued between -67.50 and -44.71, Fairly Valued between 0.85 and -44.71, Overvalued between 0.85 and 23.64, and Strongly Overvalued above 23.64. The current Forward EV/EBIT of -156.79 falls within the Strongly Undervalued range.
12.35
PS
Ascendis Pharma A/S. (ASND) has a current PS of 12.35. The 5-year average PS is 151.10. The thresholds are as follows: Strongly Undervalued below -330.37, Undervalued between -330.37 and -89.64, Fairly Valued between 391.84 and -89.64, Overvalued between 391.84 and 632.57, and Strongly Overvalued above 632.57. The current Forward PS of 12.35 falls within the Historic Trend Line -Fairly Valued range.
117.70
P/OCF
Ascendis Pharma A/S. (ASND) has a current P/OCF of 117.70. The 5-year average P/OCF is 6.51. The thresholds are as follows: Strongly Undervalued below -1590.09, Undervalued between -1590.09 and -791.79, Fairly Valued between 804.80 and -791.79, Overvalued between 804.80 and 1603.10, and Strongly Overvalued above 1603.10. The current Forward P/OCF of 117.70 falls within the Historic Trend Line -Fairly Valued range.
-746.22
P/FCF
Ascendis Pharma A/S. (ASND) has a current P/FCF of -746.22. The 5-year average P/FCF is -27.14. The thresholds are as follows: Strongly Undervalued below -137.73, Undervalued between -137.73 and -82.43, Fairly Valued between 28.16 and -82.43, Overvalued between 28.16 and 83.45, and Strongly Overvalued above 83.45. The current Forward P/FCF of -746.22 falls within the Strongly Undervalued range.
Ascendis Pharma A/S (ASND) has a current Price-to-Book (P/B) ratio of -52.27. Compared to its 3-year average P/B ratio of -19.48 , the current P/B ratio is approximately 168.39% higher. Relative to its 5-year average P/B ratio of -8.39, the current P/B ratio is about 522.97% higher. Ascendis Pharma A/S (ASND) has a Forward Free Cash Flow (FCF) yield of approximately -2.23%. Compared to its 3-year average FCF yield of -7.00%, the current FCF yield is approximately -68.11% lower. Relative to its 5-year average FCF yield of -6.61% , the current FCF yield is about -66.21% lower.
-52.27
P/B
Median3y
-19.48
Median5y
-8.39
-2.23
FCF Yield
Median3y
-7.00
Median5y
-6.61
Competitors Valuation Multiple
The average P/S ratio for ASND's competitors is 6.78, providing a benchmark for relative valuation. Ascendis Pharma A/S Corp (ASND) exhibits a P/S ratio of 12.35, which is 82.22% above the industry average. Given its robust revenue growth of 339.04%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ASND increased by 38.31% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 36.00M to 158.05M.
The secondary factor is the Margin Expansion, contributed -91.91%to the performance.
Overall, the performance of ASND in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
CHRD
Chord Energy Corp
101.060
USD
+1.54%
IVZ
Invesco Ltd
20.720
USD
+0.73%
CAE
CAE Inc
28.570
USD
+0.04%
ALV
Autoliv Inc
112.400
USD
-0.65%
SNV
Synovus Financial Corp
47.870
USD
+1.72%
FRPT
Freshpet Inc
62.740
USD
-1.94%
TREX
Trex Company Inc
59.780
USD
-2.73%
GIL
Gildan Activewear Inc
51.580
USD
-1.40%
MIDD
Middleby Corp
119.710
USD
-0.38%
ICL
ICL Group Ltd
6.190
USD
-0.16%
FAQ
Is Ascendis Pharma A/S (ASND) currently overvalued or undervalued?
Ascendis Pharma A/S (ASND) is now in the Fair zone, suggesting that its current forward PS ratio of 12.35 is considered Fairly compared with the five-year average of -20.28. The fair price of Ascendis Pharma A/S (ASND) is between 175.18 to 255.53 according to relative valuation methord.
What is Ascendis Pharma A/S (ASND) fair value?
How does ASND's valuation metrics compare to the industry average?
What is the current P/B ratio for Ascendis Pharma A/S (ASND) as of Aug 11 2025?
What is the current FCF Yield for Ascendis Pharma A/S (ASND) as of Aug 11 2025?
What is the current Forward P/E ratio for Ascendis Pharma A/S (ASND) as of Aug 11 2025?